Cell population comprising mesenchymal stem cells derived from fetal appendage, method for producing the same, and pharmaceutical composition

Abstract

Highly proliferative mesenchymal stem cells (MSCs) may be useful for the large-scale and rapid production of a cell preparation, and a cell population may include the mesenchymal stem cells. A cell population may include mesenchymal stem cells derived from a fetal appendage, wherein, in the cell population, the proportion of CD105 + mesenchymal stem cells is 50% or more, the proportion of CD200 + mesenchymal stem cells is less than 10%, and the proportion of CD106 + mesenchymal stem cells is less than 5%.

1 . A cell population comprising mesenchymal stem cells derived from the fetal appendage, wherein
 in the cell population, the proportion of CD105 +  mesenchymal stem cells is 50% or more, the proportion of CD200 +  mesenchymal stem cells is less than 10%, and the proportion of CD106 +  mesenchymal stem cells is less than 5%.   
     
     
         2 . The cell population according to  claim 1 , wherein the cell population comprises at least CD14 +  mesenchymal stem cells. 
     
     
         3 . The cell population according to  claim 2 , wherein in the cell population, the proportion of the CD14 +  mesenchymal stem cells is 5% or more. 
     
     
         4 . The cell population according to  claim 1 , wherein the mesenchymal stem cells are culturable without the arrest of proliferation up to 40 days or later after the start of ex vivo culture. 
     
     
         5 . The cell population according to  claim 1 , wherein the mesenchymal stem cells are culturable up to a population doubling level of 10 or more after the start of ex vivo culture. 
     
     
         6 . The cell population according to  claim 1 , wherein a population doubling time of the mesenchymal stem cells is 2 days or shorter. 
     
     
         7 . A pharmaceutical composition comprising the cell population according to  claim 1  and a pharmaceutically acceptable carrier.